Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu

Epidiolex Gets FDA’s Approval to Treat Rare Genetic Disease

Z-ARCHIVE-Cannabis Patent Forecast®

August 6, 2020

GW Pharmaceuticals received some good news from the FDA a few days ago as they approved the use of Epidiolex “for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older.” Previously, Epidiolex had the FDA’s approval to treat seizures from two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS).

Currently, GW Pharmaceuticals is the leading assignee of patents related to cannabis, especially for the use of cannabinoids in the treatment of epilepsy and other neurological disorders. GW’s portfolio nearly spans the entire Magic Number Cannabis Patent Forecast®. 

Explore GW Pharmaceuticals’ extensive cannabis patent portfolio at an advantage using Magic Number’s Cannabis Patent Forecast®.  

EPIDIOLEX® (cannabidiol), the First FDA Approved CBD Drug

Article Source Link

FDA


Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

For a blog.



301